In order to study the possible role of PAR2/f2rl1 in the etiology of ovarian cancer, we have undertaken the task of evaluating levels of PAR2 expression in FTs of normal and high-risk carriers of BRCA1/2 mutations. This evidence concerns the gene BRCA1 and ovarian carcinoma.